Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 43Carcinoma, Hepatocellular 19Rectal Neoplasms 10Colonic Neoplasms 10Neoplasm Metastasis 9Gastrointestinal Stromal Tumors 8Sarcoma 5Ovarian Neoplasms 5Cholangiocarcinoma 5Melanoma 4Pancreatic Neoplasms 3Osteosarcoma 3Liver Neoplasms 3Glioblastoma 3Stomach Neoplasms 2Neoplasms 2Lung Neoplasms 2Gallbladder Neoplasms 2Fatigue 2Esophageal Neoplasms 2Colorectal Cancer Metastatic 2Carcinoma, Renal Cell 2Carcinoma, Non-Small-Cell Lung 2Bile Duct Neoplasms 2Adenocarcinoma 2Urothelial Cancer (Urinary Bladder, Ureters, or Renal Pelvis Cancer) 1Thyroid Neoplasms 1Thymoma 1Squamous Cell Carcinoma of Head and Neck 1Somatostatinoma 1

Interventions

Cisplatin 24Carboplatin 19Paclitaxel 18pembrolizumab 12Gemcitabine 12Radiotherapy 9Fluorouracil 9Specimen Handling 8Magnetic Resonance Spectroscopy 7cemiplimab 6Platinum 6Nivolumab 6Docetaxel 6Cetuximab 61,2-diaminocyclohexaneplatinum II citrate 6epothilone B 5anlotinib 5Sunitinib 5Pemetrexed 5Oxaliplatin 5Everolimus 5Drug Therapy 5Cyclophosphamide 5Capecitabine 5Bevacizumab 5durvalumab 4Radiotherapy, Intensity-Modulated 4Radiation 4Erlotinib Hydrochloride 4Celecoxib 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Carcinoma × regorafenib × Clear all
NCT02115542 2021-10-12

Single Agent Regorafenib in Refractory Advanced Biliary Cancers

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Completed
39 enrolled 11 charts
Gastrointestinal

Bile Duct Diseases, Bile Duct Neoplasms, Carcinoma, Gallbladder Diseases, Gallbladder Neoplasms, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡